X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-13 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Dir | S - Sale | $6.95 | -30,000 | 282,517 | -10% | -$208,500 | ||||||
2025-06-13 | LTRN | Lantern Pharma Inc. | Fletcher Aaron G.L. | 10% | S - Sale | $3.09 | -40,000 | 1,075,952 | -4% | -$123,600 | ||||||
2025-06-13 | LTRN | Lantern Pharma Inc. | Kreis Leslie W. | 10% | S - Sale | $3.09 | -40,000 | 1,075,952 | -4% | -$123,600 | ||||||
2025-06-12 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.00 | -300 | 101,817 | 0% | -$3,000 | ||||||
| M | 2025-06-11 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale | $7.03 | -10,712 | 66,377 | -14% | -$75,348 | |||||
2025-06-11 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.85 | +5,000 | 992,910 | +1% | +$9,250 | ||||||
2025-06-11 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale | $11.40 | -400,000 | 12,278,992 | -3% | -$4,560,360 | ||||||
2025-06-11 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale | $11.40 | -400,000 | 13,190,168 | -3% | -$4,560,520 | ||||||
2025-06-11 | MIRM | Mirum Pharmaceuticals, Inc. | Fairey William | Dir | S - Sale | $48.42 | -3,203 | 2,500 | -56% | -$155,091 | ||||||
| M | 2025-06-11 | ACUT | Accustem Sciences Inc. | Cerrone Gabriele M | Dir, 10% | P - Purchase | $0.50 | +37,196 | 6,500,000 | +1% | +$18,462 | |||||
2025-06-12 | SLS | Sellas Life Sciences Group, Inc. | Van Nostrand Robert L | Dir | P - Purchase | $1.48 | +10,000 | 20,400 | +96% | +$14,800 | ||||||
| M | 2025-06-10 | LTRN | Lantern Pharma Inc. | Fletcher Aaron G.L. | 10% | S - Sale | $3.38 | -61,613 | 1,115,952 | -5% | -$208,271 | |||||
| M | 2025-06-10 | LTRN | Lantern Pharma Inc. | Kreis Leslie W. | 10% | S - Sale | $3.38 | -61,613 | 1,115,952 | -5% | -$208,271 | |||||
| D | 2025-06-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $70.61 | -2,200 | 0 | -100% | -$155,342 | |||||
| D | 2025-06-10 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $72.42 | -20,000 | 5,487 | -78% | -$1,448,475 | |||||
| M | 2025-06-10 | BHC | Bausch Health Companies Inc. | Paulson John | Dir | P - Purchase | $5.27 | +2,788,608 | 29,227,643 | +11% | +$14,700,257 | |||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $54.05 | -37,837 | 556,487 | -6% | -$2,044,940 | ||||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $54.00 | -2,358 | 167,363 | -1% | -$127,323 | ||||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $54.00 | -2,804 | 59,155 | -5% | -$151,402 | ||||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $54.00 | -2,803 | 92,231 | -3% | -$151,351 | ||||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale | $54.00 | -919 | 32,573 | -3% | -$49,625 | ||||||
2025-06-10 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $53.99 | -2,493 | 258,047 | -1% | -$134,605 | ||||||
| D | 2025-06-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale+OE | $32.88 | -20,000 | 80,195 | -20% | -$657,694 | |||||
2025-06-10 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $114.54 | -500 | 32,403 | -2% | -$57,271 | ||||||
2025-06-11 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale | $258.36 | -134 | 73,983 | 0% | -$34,620 | ||||||
| D | 2025-06-10 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $262.82 | -41,760 | 10,159,074 | 0% | -$10,975,316 | |||||
| M | 2025-06-10 | CPRX | Catalyst Pharmaceuticals, Inc. | Sundaram Preethi | Chief Strategy Officer | S - Sale | $26.41 | -3,924 | 41,081 | -9% | -$103,649 | |||||
| D | 2025-06-10 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $67.19 | -2,069 | 1,889 | -52% | -$139,016 | |||||
2025-06-10 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $15.82 | +7,930 | 2,855,000 | 0% | +$125,484 | ||||||
| DM | 2025-06-10 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $91.16 | -45,163 | 83,111 | -35% | -$4,117,067 | |||||
| DM | 2025-06-10 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $92.09 | -137,472 | 89,407 | -61% | -$12,659,257 | |||||
2025-06-10 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Gautam | Dir | S - Sale | $8.02 | -56,426 | 1,704,050 | -3% | -$452,537 | ||||||
| D | 2025-06-10 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $89.12 | -57,766 | 103,412 | -36% | -$5,148,024 | |||||
2025-06-09 | ARDX | Ardelyx, Inc. | Mott David M | Dir | P - Purchase | $3.69 | +200,000 | 2,696,871 | +8% | +$737,260 | ||||||
2025-06-09 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% | P - Purchase | $0.10 | +21,241,163 | 41,659,743 | +104% | +$2,221,826 | ||||||
2025-06-09 | TYRA | Tyra Biosciences, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $10.19 | +186,850 | 12,035,338 | +2% | +$1,904,002 | ||||||
| M | 2025-06-10 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.01 | -3,300 | 102,117 | -3% | -$33,017 | |||||
2025-06-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.34 | -6,667 | 303,309 | -2% | -$135,574 | ||||||
| M | 2025-06-10 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.40 | +169,600 | 111,482,755 | 0% | +$67,991 | |||||
| DM | 2025-06-09 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale+OE | $56.27 | -20,000 | 83,892 | -19% | -$1,125,400 | |||||
| DM | 2025-06-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Quart Barry D | Dir | S - Sale+OE | $30.35 | -27,448 | 12,546 | -69% | -$833,001 | |||||
| DM | 2025-06-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $30.48 | -70,867 | 72,363 | -49% | -$2,160,035 | |||||
| D | 2025-06-09 | AKBA | Akebia Therapeutics, Inc. | Malabre Richard C | SVP, Chief Accounting Officer | S - Sale+OE | $4.01 | -15,000 | 266,914 | -5% | -$60,150 | |||||
| D | 2025-06-09 | COLL | Collegium Pharmaceutical, Inc | Freund John Gordon | Dir | S - Sale+OE | $30.62 | -6,601 | 114,071 | -5% | -$202,149 | |||||
| D | 2025-06-10 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $40.00 | -4,292 | 5,197 | -45% | -$171,680 | |||||
2025-06-10 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $2.42 | +2,000 | 27,149 | +8% | +$4,840 | ||||||
2025-06-10 | PHIO | Phio Pharmaceuticals Corp. | Ferrara Robert L | Dir | P - Purchase | $2.42 | +2,500 | 15,666 | +19% | +$6,050 | ||||||
| M | 2025-06-09 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | S - Sale | $30.59 | -30,204 | 3,905,000 | -1% | -$923,827 | |||||
| D | 2025-06-09 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $7.37 | -5,162 | 153,378 | -3% | -$38,044 | |||||
2025-06-10 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $4.00 | -64,085 | 925,258 | -6% | -$256,340 | ||||||
| D | 2025-06-10 | CYRX | Cryoport, Inc. | Zecchini Edward J | Chief Digital, Tech Officer | S - Sale+OE | $6.85 | -51,500 | 90,411 | -36% | -$352,518 | |||||
| D | 2025-06-09 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale+OE | $7.06 | -5,622 | 77,089 | -7% | -$39,673 | |||||
| D | 2025-06-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $110.44 | -25,000 | 5,783 | -81% | -$2,761,000 | |||||
2025-06-09 | CNTX | Context Therapeutics Inc. | Lehr Martin A. | CEO | P - Purchase | $0.70 | +100,000 | 1,079,891 | +10% | +$70,080 | ||||||
| AM | 2025-06-04 | ASBP | Aspire Biopharma Holdings, Inc. | Fell Donald G. | Dir | P - Purchase | $0.39 | +20,000 | 20,000 | New | +$7,800 | |||||
2025-06-06 | CNTX | Context Therapeutics Inc. | Levit Alex C. | GC, Corp. Sec | P - Purchase | $0.58 | +20,000 | 81,983 | +32% | +$11,520 | ||||||
2025-06-06 | CNTX | Context Therapeutics Inc. | Minai-Azary Jennifer Lynn | CFO | P - Purchase | $0.64 | +40,010 | 80,010 | +100% | +$25,486 | ||||||
2025-06-09 | EOLS | Evolus, Inc. | White Albert G III | Dir | P - Purchase | $9.45 | +20,000 | 50,378 | +66% | +$189,000 | ||||||
| D | 2025-06-09 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $14.50 | -7,169 | 315,074 | -2% | -$103,951 | |||||
| M | 2025-06-06 | CPRX | Catalyst Pharmaceuticals, Inc. | McEnany Patrick J | Chairman of Board of Directors | S - Sale | $26.09 | -200,000 | 4,281,702 | -4% | -$5,217,338 | |||||
2025-06-06 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $256.11 | -700 | 237,042 | 0% | -$179,280 | ||||||
2025-06-06 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $252.39 | -1,402 | 1,703,910 | 0% | -$353,853 | ||||||
2025-06-06 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $253.15 | -1,934 | 1,167,291 | 0% | -$489,591 | ||||||
2025-06-06 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $252.77 | -5,127 | 54,152,102 | 0% | -$1,295,946 | ||||||
| D | 2025-06-06 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $68.05 | -7,031 | 19,209 | -27% | -$478,435 | |||||
2025-06-09 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $2.75 | +1,500 | 25,149 | +6% | +$4,125 | ||||||
| M | 2025-06-09 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale | $31.52 | -6,667 | 86,208 | -7% | -$210,143 | |||||
| D | 2025-06-06 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $79.82 | -200 | 63,101 | 0% | -$15,964 | |||||
| D | 2025-06-09 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $325.38 | -12,000 | 8,118 | -60% | -$3,904,496 | |||||
| M | 2025-06-06 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.41 | +86,500 | 111,313,155 | 0% | +$35,161 | |||||
2025-06-09 | AYTU | Aytu Biopharma, Inc | Disbrow Jarrett | Chief Business Officer | P - Purchase | $1.50 | +16,666 | 29,462 | +130% | +$24,999 | ||||||
2025-06-09 | AYTU | Aytu Biopharma, Inc | Disbrow Joshua R. | CEO | P - Purchase | $1.50 | +66,666 | 153,257 | +77% | +$99,999 | ||||||
2025-06-06 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $50.00 | -2,996 | 56,725 | -5% | -$149,800 | ||||||
| M | 2025-06-06 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.01 | -2,900 | 103,864 | -3% | -$29,021 | |||||
| DM | 2025-06-05 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $54.52 | -37,500 | 169,721 | -18% | -$2,044,634 | |||||
2025-06-05 | RFL | Rafael Holdings, Inc. | Jonas Howard S | Exec COB, CEO, Pres, 10% | P - Purchase | $1.28 | +13,080,457 | 14,688,994 | +813% | +$16,742,985 | ||||||
| M | 2025-06-05 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.74 | +10,100 | 987,910 | +1% | +$17,545 | |||||
| D | 2025-06-05 | IMUX | Immunic, Inc. | Tardio Jason | Pres, COO | P - Purchase | $0.79 | +12,512 | 12,512 | New | +$9,884 | |||||
2025-06-05 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $1.40 | +21,000 | 734,460 | +3% | +$29,400 | ||||||
| M | 2025-06-04 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.41 | +26,000 | 111,226,655 | 0% | +$10,530 | |||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $6.76 | -17,795 | 491,246 | -3% | -$120,294 | ||||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $6.76 | -50,676 | 1,303,761 | -4% | -$342,570 | ||||||
| D | 2025-06-05 | XENE | Xenon Pharmaceuticals Inc. | Gannon Steven | Dir | S - Sale+OE | $30.48 | -3 | 7,141 | 0% | -$91 | |||||
2025-06-06 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $6.76 | -10,470 | 378,245 | -3% | -$70,777 | ||||||
| M | 2025-06-04 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $11.30 | -748,230 | 51,784,238 | -1% | -$8,454,808 | |||||
| M | 2025-06-04 | ORGO | Organogenesis Holdings Inc. | Freedman Lori | Chief Admin., Legal Officer | P - Purchase | $2.88 | +252,264 | 846,459 | +42% | +$725,290 | |||||
| M | 2025-06-04 | ASBP | Aspire Biopharma Holdings, Inc. | Fell Donald G. | Dir | P - Purchase | $0.39 | +20,000 | 20,000 | New | +$7,800 | |||||
| D | 2025-06-04 | IMUX | Immunic, Inc. | Vitt Daniel | CEO, Dir | P - Purchase | $0.77 | +15,000 | 391,877 | +4% | +$11,550 | |||||
2025-06-05 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $73.50 | -1,879 | 67,718 | -3% | -$138,107 | ||||||
2025-06-05 | KRON | Kronos Bio, Inc. | Knobelman Deborah | Pres, Interim CEO | S - Sale | $0.87 | -24,838 | 139,422 | -15% | -$21,554 | ||||||
| M | 2025-06-04 | TYRA | Tyra Biosciences, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.70 | +1,211,198 | 11,848,488 | +11% | +$11,751,304 | |||||
2025-06-04 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% | S - Sale | $10.20 | -3,000,000 | 3,906,181 | -43% | -$30,600,000 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $13.35 | -4,060 | 174,179 | -2% | -$54,201 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $13.35 | -1,342 | 92,815 | -1% | -$17,916 | ||||||
2025-06-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $13.35 | -146 | 95,911 | 0% | -$1,949 | ||||||
| M | 2025-06-04 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.34 | +2,268 | 8,852,607 | 0% | +$30,247 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $5.11 | +945 | 285,698 | 0% | +$4,824 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $5.11 | +168 | 43,168 | 0% | +$858 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $5.11 | +84 | 32,569 | 0% | +$429 | |||||
| M | 2025-05-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $5.11 | +168 | 5,699,260 | 0% | +$858 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |